Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
LSL Pharma GroupTSXV:LSL +2.82%48 Debt-to-Equity is 1.81 as of Mar. 2026, which is 59% above its 10-year median of 1.14. GuruFocus rates TSXV:LSL with a GF Score™ of 48/100 and a GF Value™ of C$0.73 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 813 Drug Manufacturers companies, LSL Pharma Group ranks worse than 94.34% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for LSL Pharma Group's Debt-to-Equity or its related term are showing as below:
TSXV:LSL'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0.69 Med: 1.14 Max: 2.81
Current: 1.81
During the past 6 years, the highest Debt-to-Equity Ratio of LSL Pharma Group was 2.81. The lowest was 0.69. And the median was 1.14.
TSXV:LSL's Debt-to-Equity is ranked worse than 94.34% of 813
companies
in the Drug Manufacturers industry
Industry Median: 0.27
vs TSXV:LSL: 1.81
LSL Pharma Group (TSXV:LSL) Debt-to-Equity Explanation
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
LSL Pharma Group Debt-to-Equity Related Terms
LSL Pharma Group Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for LSL Pharma Group's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, LSL Pharma Group's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
LSL Pharma Group Debt-to-Equity vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, LSL Pharma Group's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where LSL Pharma Group's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LSL Pharma Group (TSXV:LSL) has a Debt-to-Equity of 1.81 as of Mar. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on LSL Pharma Group and its competitors. This is 59% above median its historical median of 1.14. Over the past decade, LSL Pharma Group's Debt-to-Equity has ranged from 0.69 to 2.81. According to the industry distribution chart, LSL Pharma Group ranks #767 out of 813 companies in the Drug Manufacturers industry, placing it in the top 94.3%.
Is LSL Pharma Group's Debt-to-Equity too high?
LSL Pharma Group's current Debt-to-Equity of 1.81 is 59% above median its 10-year median of 1.14. Over the past 10 years, this metric has ranged from a low of 0.69 to a high of 2.81. The Drug Manufacturers industry median Debt-to-Equity is 0.27. LSL Pharma Group's value of 1.81 is 570.4% above this industry median. Based on the distribution chart, LSL Pharma Group ranks #767 out of 813 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, LSL Pharma Group has a GF Score™ of 48/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does LSL Pharma Group's Debt-to-Equity compare to ZTS?
According to the Drug Manufacturers industry distribution chart, LSL Pharma Group ranks #767 out of 813 companies for Debt-to-Equity. This places LSL Pharma Group in the lower half of its industry. The industry median Debt-to-Equity is 0.27. LSL Pharma Group's value of 1.81 is 570.4% above this benchmark. Historically, LSL Pharma Group's own Debt-to-Equity has ranged from 0.69 to 2.81 over the past decade. While the company's 10-year median is 1.14 vs. the industry median of 0.27, LSL Pharma Group has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Drug Manufacturers company?
The median Debt-to-Equity among Drug Manufacturers companies is 0.27, based on 813 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. LSL Pharma Group's current Debt-to-Equity of 1.81 is 570.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on LSL Pharma Group and its competitors. For the Drug Manufacturers industry, the median Debt-to-Equity is 0.27 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. LSL Pharma Group's current Debt-to-Equity is 1.81, which is 59% above median its own 10-year median of 1.14. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is LSL Pharma Group stock overvalued right now?
Based on GuruFocus' analysis, LSL Pharma Group (TSXV:LSL) is currently considered Possible Value Trap. The stock's GF Value™ is C$0.73, compared to a current price of C$0.37 — trading 50% below its estimated fair value. The current Debt-to-Equity is 1.81, which is 59% above median its 10-year median of 1.14 and 570.4% above the Drug Manufacturers industry median of 0.27. LSL Pharma Group's overall GF Score™ is 48/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For LSL Pharma Group (TSXV:LSL), the current Debt-to-Equity is 1.81 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is LSL Pharma Group (TSXV:LSL) Overvalued in 2026?
Based on GuruFocus' analysis, LSL Pharma Group stock appears to be undervalued.
The current stock price of C$0.37 is trading 50% below its estimated GF Value™ of C$0.73.
GuruFocus considers LSL Pharma Group to be Possible Value Trap.
Key valuation signals for TSXV:LSL:
Debt-to-Equity: 1.81 (59% above median its 10-year median of 1.14)
GF Value™: C$0.73 vs. price of C$0.37 (50% below fair value)
Industry Position: 570.4% above the Drug Manufacturers median (#767 of 813)
No single metric tells the full story. See the TSXV:LSL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
LSL Pharma Group Inc develops, manufactures and commercializes sterile pharmaceutical products, cosmetic products and natural health products. It operates in three segments CMO activities include four operating entities LSL Laboratory, Dermolab, Du-Var, and VSI; Integrated Eye-care pharmaceutical company which includes sterile Eye-care manufacturing operation; and Private Label Business includes Juno OTC which commercializes pharmaceutical products with a focus on private label, over the counter (OTC) products. It derives majority of revenue from CMO activities segment.
48GF Score
Get the complete analysis for TSXV:LSL
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSXV:LSL has been successfully added to your 
